Ryan D. Chow

Rational Design of Immune Gene Therapy Combinations via In Vivo CRISPR Activation Screen of Tumor Microenvironment Modulators

Feifei Zhang, Chuanpeng Dong, Ryan D. Chow, Shan Xin et autres

us (code pays fourni par la source)

Table S4 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

Ryan D. Chow, Tai Michaels, Stefania Bellone, Tobias M.P. Hartwich et autres

Table S3 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

Ryan D. Chow, Tai Michaels, Stefania Bellone, Tobias M.P. Hartwich et autres

Supplementary Figures from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

Ryan D. Chow, Tai Michaels, Stefania Bellone, Tobias M.P. Hartwich et autres

Table S2 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

Ryan D. Chow, Tai Michaels, Stefania Bellone, Tobias M.P. Hartwich et autres

Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

Ryan D. Chow, Tai Michaels, Stefania Bellone, Tobias M.P. Hartwich et autres

Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction

Henry K. Litt, Ronac Mamtani, Ryan D. Chow

us (code pays fourni par la source)

Brain-wide Genome Editing via STEP-RNPs for Treatment of Angelman Syndrome

Xiaona Lu, Ying Xie, Youmei Bao, Jiang Yu et autres

us (code pays fourni par la source)

Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer

Ryan D. Chow, Ramy Sedhom, Ronac Mamtani

us (code pays fourni par la source)

Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma

Ryan D. Chow, Ronac Mamtani

us (code pays fourni par la source)

Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma

Ryan D. Chow, Ronac Mamtani

us (code pays fourni par la source)

Abstract LB434: Discovery and preclinical evaluation of ATM-5292: A potent and selective RNA targeting splice modulator for the treatment of non small cell lung cancer (NSCLC) and breast cancer, enabled by the PARSE™ machine learning platform

Minna Bui, Praveen Kumar, Timothy Sproul, Michael J. Luzzio et autres

us (code pays fourni par la source)